CA3066518C - Immunotherapie pour carcinome hepatocellulaire - Google Patents

Immunotherapie pour carcinome hepatocellulaire

Info

Publication number
CA3066518C
CA3066518C CA3066518A CA3066518A CA3066518C CA 3066518 C CA3066518 C CA 3066518C CA 3066518 A CA3066518 A CA 3066518A CA 3066518 A CA3066518 A CA 3066518A CA 3066518 C CA3066518 C CA 3066518C
Authority
CA
Canada
Prior art keywords
antibody
hcc
seq
cdr
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3066518A
Other languages
English (en)
Other versions
CA3066518A1 (fr
Inventor
Lai Wang
Kang Li
Qinzhou QI
Jeannie HOU
Zhong Wu
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Priority claimed from PCT/CN2018/092827 external-priority patent/WO2019001417A1/fr
Publication of CA3066518A1 publication Critical patent/CA3066518A1/fr
Application granted granted Critical
Publication of CA3066518C publication Critical patent/CA3066518C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne un procédé pour la prévention, le retard de progression ou le traitement d'un carcinome hépatocellulaire chez un sujet, comprenant l'administration au sujet en ayant besoin d'une quantité efficace sur le plan thérapeutique d'un anticorps anti-PD-1, qui est un anticorps ou un fragment d'antigène de liaison à celui-ci, se liant de manière spécifique à PD-1 humain.
CA3066518A 2017-06-26 2018-06-26 Immunotherapie pour carcinome hepatocellulaire Active CA3066518C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762524967P 2017-06-26 2017-06-26
US62/524,967 2017-06-26
CNPCT/CN2017/090397 2017-06-27
CN2017090397 2017-06-27
PCT/CN2018/092827 WO2019001417A1 (fr) 2017-06-26 2018-06-26 Immunothérapie pour carcinome hépatocellulaire

Publications (2)

Publication Number Publication Date
CA3066518A1 CA3066518A1 (fr) 2019-01-03
CA3066518C true CA3066518C (fr) 2025-10-07

Family

ID=

Similar Documents

Publication Publication Date Title
US11597768B2 (en) Immunotherapy for hepatocellular carcinoma
US20210040213A1 (en) Immunomonotherapy for urothelial carcinoma
JP6914283B2 (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
JP2023542291A (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
CA3091217A1 (fr) Conjugues de medicament et d'anticorps anti-facteur tissulaire, et leur utilisation dans le traitement du cancer
EP4149547A1 (fr) Compositions et méthodes pour le traitement du cancer
US20220387404A1 (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
US20250101097A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
KR20240038008A (ko) 암 치료 방법 및 조성물
CN119587691A (zh) 抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤
CN120529917A (zh) 使用抗CTLA4抗体与Pembrolizumab组合治疗癌症的方法
CN121622859A (zh) TGF-β受体融合蛋白在制备治疗胃及胃食管结合部腺癌的药物中的用途
WO2025100428A1 (fr) Combinaison d'anticorps anti-cd147 et d'un autre agent antitumoral
WO2025076389A1 (fr) Méthodes de traitement de tumeurs solides avancées avec conjugués anticorps-médicament b7-h4
KR20250075750A (ko) 항-ctla4 항체를 사용한 암의 치료 방법
CN121693347A (zh) 使用可活化抗ctla4抗体与pembrolizumab组合治疗癌症的方法
CN120513101A (zh) 抗pvrig/抗tigit双特异性抗体在治疗恶性肿瘤中的用途
CN120035606A (zh) 一种治疗实体瘤的方法
CN114601924A (zh) 抗pd-1抗体或其抗原结合片段治疗鳞状非小细胞肺癌的方法
HK40117614A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
HK40127073A (zh) 使用抗ctla4抗体治疗胰腺癌的方法